You are here:

desmopressin (Noqdirna)

Advice

following a resubmission:

desmopressin oral lyophilisate (Noqdirna®) is accepted for restricted use within NHS Scotland.

Indication under review: Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.

SMC restriction: For use in patients aged 65 years and over.

Two phase III, placebo-controlled studies demonstrated that desmopressin, at licensed doses over three months, significantly reduced the mean number of nocturnal voids and resulted in higher proportions of responders compared with placebo, in patients with nocturia.

Drug Details

Drug Name: desmopressin (Noqdirna)
SMC Drug ID: 1218/17
Manufacturer: Ferring Pharmaceuticals Ltd
Indication: symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.
BNF Category:
Submission Type: Resubmission
Status: Restricted
Date Advice Published: 7 August 2017

Archived Advice

Full submission 13 February 2017

Back